ITEMS IN AFP WITH KEYWORD:

Diabetes

Nov 15, 2017 Issue
Glucose Management in Hospitalized Patients [Article]

Challenges to glucose control in hospitalized patients with type 2 diabetes mellitus include determining blood glucose targets, judicious use of oral diabetes medications, and implementing appropriate insulin regimens. Home oral diabetes medications should be continued in the absence of contraindications. Insulin dosing is based on patient factors, such as current oral intake, comorbidities, baseline diabetic control, and experience with prior insulin therapy. Sliding scale insulin regimens are not recommended.


Oct 15, 2017 Issue
Newer Oral Hypoglycemics Do Not Increase or Decrease Mortality [POEMs]

This seems like a strange question considering that the goal is to decrease mortality with drug therapy. Nevertheless, this study showed that the new kids on the diabetes block—exenatide (Byetta), dulaglutide (Trulicity), sitagliptin (Januvia), saxagliptin (Onglyza), and others—do not increase mortality, even in patients with cardiovascular risk.


Oct 15, 2017 Issue
Dulaglutide (Trulicity) for Type 2 Diabetes Mellitus [STEPS]

Dulaglutide is an easy-to-use, once-weekly injectable therapy for the treatment of type 2 diabetes in adults. It produces a modest decrease in A1C levels with only a small risk of severe hypoglycemia. The small average weight loss it induces may be an advantage for some patients.


Oct 1, 2017 Issue
Type 2 Diabetes Mellitus: ACP Releases Updated Recommendations for Oral Pharmacologic Treatment [Practice Guidelines]

The American College of Physicians (ACP) previously released guidelines in 2012 regarding the effectiveness and safety of oral pharmacologic treatment for type 2 diabetes; however, new evidence has emerged and new drugs have been approved by the U.S. Food and Drug Administration. For this reason, th...


Sep 15, 2017 Issue
Diabetes Self-Management: Facilitating Lifestyle Change [Article]

Help patients with prediabetes or diabetes achieve dietary and physical activity goals using the strategies discussed in this article.


Aug 15, 2017 Issue
Lixisenatide (Adlyxin) for Type 2 Diabetes Mellitus [STEPS]

ixisenatide is an easy-to-use, once-daily injectable therapy for the treatment of type 2 diabetes in adults. It is at least as effective as exenatide at reducing A1C and body weight, with similar rates of gastrointestinal adverse effects.


Apr 15, 2017 Issue
Albiglutide (Tanzeum) for Diabetes Mellitus [STEPS]

Reductions in A1C are less with albiglutide than with the first-line therapy metformin, and albiglutide costs significantly more than metformin and sulfonylureas. Albiglutide's ability to reduce diabetes-related morbidity and major cardiovascular events is unknown.


Mar 15, 2017 Issue
Detrimental Effect of Tight Glucose Control on CV Mortality Persists Over Nine Years [POEMs]

The initial Action to Control Cardiovascular Risk in Diabetes (ACCORD) study, which compared standard treatment with intensive control, found that despite good intentions, cardiovascular (CV) and overall mortality are significantly higher when blood glucose levels are lower.


Mar 15, 2017 Issue
Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus [POEMs]

Semaglutide significantly reduced the composite outcome of CV death, nonfatal myocardial infarction, and nonfatal stroke (number needed to treat [NNT] = 43 over 2.1 years). It was generally well tolerated, and it reduced body weight by approximately 6.4 to 9.5 lb (2.9 to 4.3 kg).


Jan 1, 2017 Issue
ADA Updates Standards of Medical Care for Patients with Diabetes Mellitus [Practice Guidelines]

The American Diabetes Association (ADA) recently updated its standards of care to provide the components of diabetes care, general treatment goals, and tools to evaluate the quality of care. Key changes in the 2016 update include new screening recommendations, clarification of diagnostic testing, an...


Pages: 1 2 3 4 5 6 7 8 9 10 ... 15 Next


Email Alerts

Don't miss a single issue. Sign up for the free AFP email table of contents.

Sign Up Now